 UNIONDALE, N.Y., Aug. 03, 2021 GLOBE NEWSWIRE -- Angion Biomedica Corp NASDAQ:ANGN, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor TKI being developed for the treatment of fibrotic diseases. Angion also announced the FDAs acceptance of an IND application supporting the initiation of a Phase 2 trial in patients with primary proteinuric kidney diseases in 2021. Additionally, the Company announced it will host a Virtual Fibrosis RD Day on September 20, 2021. 